Lung Cancer TALK: A Review of Data from the IASLC 2020 World Conference on Lung Cancer - Episode 3

WCLC Updates in Immunotherapy for NSCLC

February 26, 2021
Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center

Sarah Goldberg, MD, MPH, Yale School of Medicine

Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center

Heather A. Wakelee, MD, Stanford University Medical Center

Key opinion leaders discuss recent trial data on the clinical efficacy of immunotherapy for the treatment of non–small cell lung cancer (NSCLC).

Data from the following clinical trials are discussed:

  • OA01.06 - Randomized Phase 2 Study of Nivolumab (N) Versus Nivolumab and Ipilimumab (NI) Combination in EGFR-Mutant NSCLC
  • PS01.09 - Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo as 1L Therapy for Metastatic NSCLC of PD-L1 TPS ≥50%: KEYNOTE-598
  • OA01.03- Clinical Benefits of First-line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC